BRIEF

on Fortvita Biologics

Fortvita Biologics Gets Positive Opinion on Lung Cancer Treatment

Fortvita Biologics has received its first positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This opinion recommends the marketing authorization of Zybrivo® (sintilimab) for first-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC) in eligible adults. If approved by the European Commission, this drug will expand treatment options across Europe.

The recommendation is based on Phase 3 ORIENT-11 study results, which demonstrated a significant reduction in disease progression risk when sintilimab was combined with chemotherapy. The study involved 397 participants with advanced or metastatic non-squamous NSCLC, showing improved progression-free and overall survival rates compared to placebo.

Zybrivo, combined with chemotherapy, showed a 52% reduction in disease progression risk. If approved, it will be available in EU member states, Iceland, Norway, and Liechtenstein. This milestone highlights Fortvita's commitment to expanding access to innovative therapies globally.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Fortvita Biologics news